Update (May 23): Pfizer and BioNTech today announced that unpublished data show the companies’ COVID-19 vaccine is about 80 percent effective at preventing symptomatic infections in children between the ages of 6 months and under 5 years when a third dose is administered at least two months after the first two. While data are still trickling in, the announcement suggests that the three-dose regimen prompts an immune response comparable to that triggered in adults by the existing, two-dose regimen, researchers tell The New York Times.
Update (March 2): New data released yesterday by the Centers for Disease Control and Prevention (CDC) presents a more complete view of the protections that the Pfizer/BioNTech vaccine offers young children, according to the Associated Press. The CDC analyzed pediatric hospitalization rates from April 2021 through January 2022 and found that the vaccine was 74 percent effective at preventing hospitalization among 5- to 11-year-olds and ...
